XML 109 R77.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements and Licensing Agreements, Novartis (Details)
$ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 27, 2019
USD ($)
Jul. 31, 2017
USD ($)
May 31, 2015
USD ($)
Mar. 31, 2017
USD ($)
PerformanceObligation
shares
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Mar. 01, 2019
USD ($)
shares
Jan. 31, 2017
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Proceeds from sale of common stock to Novartis in a private placement         $ 0 $ 50,000 $ 0    
Revenue     $ 91,200   599,674 514,179 372,776    
Deferred revenue           233,362      
Subsequent Event [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Sublicense fee to be paid in stock by Akcea for license of AKCEA-AP)(a)-L               $ 75,000  
Additional shares of Akcea stock to be received for license of AKCEA-APO(a)-L (in shares) | shares               2.8  
R&D [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Revenue         344,752 394,165 $ 350,009    
Novartis [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Shares issued (in shares) | shares       1.6          
Proceeds from sale of common stock       $ 100,000          
Additional amount of common stock required to be purchased                 $ 50,000
Number of separate performance obligations | PerformanceObligation       4          
Transaction price       $ 108,400          
Premium received on shares issued       28,400          
Potential premium received if common stock is purchased in the future       5,000          
Deferred revenue         $ 28,800 $ 70,700      
Novartis [Member] | Revenue [Member] | Strategic Partner [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Concentration percentage         8.00% 8.00%      
Novartis [Member] | R&D Services for AKCEA-APO(a)-L [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Transaction price       64,000          
Novartis [Member] | Delivery of AKCEA-APO(a)-L [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Transaction price       1,500          
Novartis [Member] | R&D Services for AKCEA-APOCIII-L [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Transaction price       40,100          
Novartis [Member] | Delivery of AKCEA-APOCIII-L [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Transaction price       2,800          
Novartis [Member] | R&D [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Revenue         $ 50,600 $ 43,400      
Akcea [Member] | Novartis [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Upfront payment received       75,000          
Portion of upfront payment retained       60,000          
Portion of upfront payment paid as a sublicense fee       15,000          
License fee receivable per drug         $ 150,000        
Percentage of license fees, milestone payments and royalties paid as sublicense fee         50.00%        
Additional amount of common stock required to be purchased       $ 50,000          
Proceeds from sale of common stock to Novartis in a private placement   $ 50,000              
Akcea [Member] | Novartis [Member] | License Fees [Member] | Subsequent Event [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Revenue $ 150,000                
Akcea [Member] | Novartis [Member] | AKCEA-APO(a)-L [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Maximum amount of payments receivable for milestones         $ 675,000        
Maximum amount of payments receivable for development milestones         25,000        
Maximum amount of payments receivable for regulatory milestones         290,000        
Maximum amount of payments receivable for commercialization milestones         $ 360,000        
Royalty percentage received on sales of drug         20.00%        
Akcea [Member] | Novartis [Member] | AKCEA-APOCIII-L [Member]                  
Collaborative Arrangement and Licensing Agreement [Abstract]                  
Maximum amount of payments receivable for milestones         $ 530,000        
Maximum amount of payments receivable for development milestones         25,000        
Maximum amount of payments receivable for regulatory milestones         240,000        
Maximum amount of payments receivable for commercialization milestones         $ 265,000        
Royalty percentage received on sales of drug         20.00%